$21.870
-0.070 (-0.32%)終値時点
GPCR の収益性とマージン
Evaluating the bottom line, Structure Therapeutics Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -20.21%, provide a clear picture of how effectively GPCR converts its operational activities into shareholder value.
GPCR の同業比較
In the context of the broader market, GPCR competes directly with industry leaders such as INVA and RARE. With a market capitalization of $1.51B, it holds a significant position in the sector. When comparing efficiency, GPCR's gross margin of N/A stands against INVA's 75.77% and RARE's 84.11%. Such benchmarking helps identify whether Structure Therapeutics Inc. is trading at a premium or discount relative to its financial performance.
Structure Therapeutics Inc の財務パフォーマンス
The company has shown significant losses, with a net income of -106,159,000 USD in Q2 2026 and an EPS of -0.49, indicating ongoing financial struggles.
Financials
本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。